Back to Search
Start Over
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- Source :
- Cancers, Cancers, MDPI, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩, Cancers, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩, Cancers, Vol 11, Iss 7, p 1033 (2019)
- Publication Year :
- 2019
- Publisher :
- MDPI AG, 2019.
-
Abstract
- International audience; Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few years, anti-PD1/PD-L1 (Programmed death-ligand 1) agents have been evaluated in breast cancer, particularly in the triple negative subtype, with promising results observed when delivered as monotherapy or in combination with conventional treatments. In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer. In addition, we will discuss the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
[SDV.CAN]Life Sciences [q-bio]/Cancer
Review
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
lcsh:RC254-282
03 medical and health sciences
breast cancer
0302 clinical medicine
Breast cancer
PDL1
Internal medicine
PD-L1
medicine
[SDV.BC] Life Sciences [q-bio]/Cellular Biology
Triple-negative breast cancer
biology
business.industry
Melanoma
[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
Immunotherapy
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Immune checkpoint
3. Good health
Blockade
[SDV] Life Sciences [q-bio]
PD1
030104 developmental biology
030220 oncology & carcinogenesis
Concomitant
triple-negative breast cancer
biology.protein
immunotherapy
business
Subjects
Details
- ISSN :
- 20726694
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Cancers
- Accession number :
- edsair.doi.dedup.....715d0a8b04d79b6ae6f1ac8b0845b958
- Full Text :
- https://doi.org/10.3390/cancers11071033